Three Decades of Sleep Research Yields Breakthrough Apnea Drug

A new sleep apnea drug emerging from three decades of University of Toronto research could transform treatment for a condition affecting 1.6 billion adults globally. With less than 10% of those with sleep apnea currently diagnosed, this pharmaceutical breakthrough targeting the neurological pathways driving the condition offers hope for improved health outcomes. The drug's successful phase 3 trials mark a significant step toward addressing one of medicine's most underdiagnosed yet serious sleep disorders.